ClinicalTrials.gg
Enrolling by invitationNCT06169579Updated Sep 21, 2026

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

A Phase 1 interventional study of ND-003 tablets and ND-003 tablets in Advanced Solid Tumor, sponsored by Shenzhen NewDEL Biotech, Co., Ltd. Enrolling by invitation at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Shenzhen NewDEL Biotech, Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.

Read the detailed description

The trial will be conducted in 2 parts: an initial dose escalation phase of drug ND-003 tablets in patients with solid tumors will be followed by an expansion phase in subjects with solid tumors harboring NTRK or RET Fusion or Mutation.

The objectives of the study are to determine the safety, tolerability, pharmacokinetic and pharmacodynamics profiles, as well as preliminary efficacy of orally administered ND-003 in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Shenzhen NewDEL Biotech, Co., Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with advanced malignant solid tumors confirmed by histology or cytology.
  2. Subjects have previously received standard treatment with failure (including disease progression or toxicity intolerance), or have no available standard treatment plans, or have to standard treatment.
  3. In the dose escalation phase, NTRK or RET gene fusion status is not an eligibility criterion, but subjects harboring NTRK or RET fusion or mutation will be prioritized. However, in the dose expansion phase, subjects must have confirmed NTRK or RET gene fusion/mutation (histologic or cytological genetic testing results are acceptable) .
  4. Patients have at least one evaluable lesion according to version 1.1 evaluation criteria ( Revised RECIST Guidelines (version 1.1) );
  5. Subjects must be 18 years or older (no limitation by sex or maximum age) on the day of signing .
  6. Have an (ECOG) Performance status of 0 to 2.
  7. Have a projected of at least 12 weeks .
  8. Have adequate organ and bone marrow function to meet laboratory examination standards.
  9. Fertile male subjects and female subjects agree to use highly effective from the time of signing informed consent until 6 months after the final dose of product. Childbearing potential female subjects include premenopausal women and women within 2 years after menopause; Pregnancy testing results for childbearing potential female subjects within ≤ 7 days before the first administration must be negative.
  10. Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.

Exclusion criteria

Exclusion criteria:

  1. Known to ND-003 or any of its constituents.
  2. Previous exposure to ND-003.
  3. Subjects participated or are currently participating in clinical trials of other drugs or medical devices within 4 weeks prior to the first administration.
  4. Subjects underwent major surgery within 4 weeks before the first administration or had a surgical plan during the study period.
  5. Received systemic anti-tumor drug therapy such as chemotherapy, macromolecular targeted therapy, endocrine therapy within 3 weeks before the first administration (subjects have previously used nitrosourea or mitomycin C with a of at least 6 weeks; subjects have previously used oral fluorouracil drugs or small molecule targeted drugs with a washout period of at least 2 weeks or 5 half-lives, whichever is the longer.) or radiation therapy, or immunotherapy within 4 weeks before administration.
  6. Use traditional Chinese patent medicines with anti-tumor effect within 2 weeks before the first administration.
  7. Receipt of within 4 weeks prior to study drug administration or plan to receive them during the study period, including but not limited to: measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus calmette-guerin (BCG) and typhoid vaccines.
  8. Subjects who used known concomitant drugs that can prolong the and/or CYP2C8, strong inhibitors and/or inducers within 7 days before the first administration, as well as those who need to continue using the aforementioned drugs during the study period.
  9. Subjects who have suffered from another type of malignant tumor within the past 5 years, excluding those who have received curative treatment for cervical cancer in situ, non melanoma skin cancer, localized prostate cancer, ductal cancer in situ, and other extremely low-risk malignant tumors.
  10. Loss or donation of blood > 500 mL (within 3 months before the first administration).
  11. Donation of bone marrow or peripheral stem cells (within 3 months before the first administration).
  12. Uncontrolled or symptomatic central nervous system (CNS) including symptomatic or meningeal metastasis or spinal cord compression; but the following patients are allowed to be included: a. subjects with treated brain metastasis (such as surgery or radiation therapy), there was no progress in imaging and/or no neurological symptoms or signs appeared after treatment at least 4 weeks before the first administration, there was no evidence of new brain metastasis or increased metastasis, and systemic hormone therapy (dosage>10 mg/day of prednisone or other effective hormones) was stopped at least 4 weeks before the first administration; b. Untreated and asymptomatic subjects with brain metastases do not require , and the length of brain metastases are ≤ 1.5 cm.
  13. Suffering from uncontrollable diseases, including but not limited to:

1)Existence of persistent or active infections (including bacteria, fungi, viruses, etc.) that require antibiotic, antifungal, or antiviral treatment; 2)Acute coronary syndrome, congestive heart failure ( Cardiac Function Classification ≥ Level II), (LVEF)\<50%, cerebrovascular accident, , stroke, deep vein thrombosis, pulmonary embolism, aneurysm, arterial dissection, or other level 3 or above cardiovascular and cerebrovascular events occurred within 6 months before the first administration; 3)Investigator considers that arrhythmias (such as bradycardia) with clinical significant or conduction abnormalities, congenital long QT interval syndrome or Fridericia's corrected QTc (corrected QT interval) are unmeasurable or QTcF>450 msec; 4)Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or hypotension (systolic blood pressure less than 80 mmHg and/or diastolic blood pressure less than 50 mmHg); 5)Uncontrolled hyperglycemia; 6)Active peptic ulcer disease or gastritis, active hemorrhagic disease; 7)Mental illness/social conditions that affect patients' compliance with clinical trials and their ability to sign written forms.

14.Have family history of long QT syndrome or unexplained sudden death in first degree relatives under the age of 40.

15.Unable to swallow medication orally, have gastrointestinal abnormalities with clinical significant (such as after gastrointestinal resection, gastrointestinal anastomosis, chronic diarrhea, and intestinal obstruction), or have significant impact on gastrointestinal absorption as determined by the investigator 16.Individuals with difficulty in venous blood collection (such as fainting or fainting history due to syringe) 17.History of drug or alcohol abuse . 18. (HIV) antibodies positive or active syphilis or active pulmonary tuberculosis (determined by the investigator based on the tuberculin test or γ- Interferon release test [T-SPOT test] results, imaging examination results and comprehensive judgment of clinical symptoms) or virus antibody positive and hepatitis C virus (HCV) RNA positive, or active patients (hepatitis B surface antigen positive and HBV (Hepatitis B virus honeybee venom) DNA ≥ the value).

19.Failure to recover from any AE related to previous surgical procedures and previous cancer treatment ( 5.0 rating to ≤ 1), except for the following situations: a. hair loss; b. Level 1 toxicity without clinical significance, such as lymphopenia.

20.Pregnant or lactating women, or planning to conceive during the study period.

21.Investigator considers that the subjects may have other situations that may affect compliance or may not be suitable to participate in this trial.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    ND-003 tablets_Dose 1

    Adult patients with solid tumors receiving 40 mg of ND-003 tablets once daily (dose escalation cohort).

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Dose 2

    Adult patients with solid tumors receiving 80 mg of ND-003 tablets once daily (dose escalation cohort).

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Dose 3

    Adult patients with solid tumors receiving 160 mg of ND-003 tablets once daily (dose escalation cohort).

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Dose 4

    Adult patients with solid tumors receiving 300 mg of ND-003 tablets once daily (dose escalation cohort).

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Dose 5

    Adult patients with solid tumors receiving 500 mg of ND-003 tablets once daily (dose escalation cohort).

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Dose 6

    Adult patients with solid tumors receiving 800 mg of ND-003 tablets once daily (dose escalation cohort).

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Expansion 1

    Adults patients with solid tumors harboring NTRK or RET Fusion or Mutation (dose expansion cohort). Patients receive either the recommended or maximum tolerated dose of ND-003 tablets as determined in the dose escalation part, one to two dose cohorts are set.

    Drug: ND-003 tablets

  • Experimental
    ND-003 tablets_Expansion 2

    Adults patients with solid tumors harboring NTRK or RET Fusion or Mutation (dose expansion cohort). Patients receive either the recommended or maximum tolerated dose of ND-003 tablets as determined in the dose escalation part, one to two dose cohorts are set.

    Drug: ND-003 tablets

Interventions

  • ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally over continuous 28-days cycles.

    Also known as: ND003 tablets

  • ND-003 tablets will be administered orally over continuous 28-days cycles.

    Also known as: ND003 tablets

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLT)

    DLT is defined as adverse events (graded according to NCI CTCAE ver5.0) assessed by the investigator to be definitely/probably/possibly related to the investigational product

    Time frame: 4 days after single oral administration and the first cycle of multiple administration (28 days)

  2. Maximum tolerated dose (MTD)

    MTD is defined as the highest dose level at which fewer than 1 of 6 subjects experienced DLT.

    Time frame: 4 days after single oral administration and the first cycle of multiple administration (28 days)

  3. Adverse Events (AE) assessed by CTCAE ver5.0.

    Number of participants with treatment-related adverse events as assessed by CTCAE ver5.0.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. maximum concentration (Cmax)

    The drug maximum concentration reaches when the absorption rate is equal to the elimination rate at a single dose.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours after at a singe dose administration of ND-003

  2. Time to maximum concentration (Tmax)

    Time required to reach peak drug concentration after a single administration.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours after at a singe dose administration of ND-003

  3. Elimination Half-life (t1/2)

    Elimination Half-life (t1/2) refers to the time required to eliminate 50% of the drug from the body.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours after a single dose administration.

  4. Clearance (CL/F)

    Clearance (CL) describes how the body effectively eliminate drugs from the systemic circulation, typically defined as the volume of drug-containing plasma eliminated from the body per unit time.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours after a single dose administration.

  5. AUC from time 0 to last time of quantifiable concentration (AUC0-t)

    Area under the plasma concentration-time curve from the initial administration to the last measurable concentration point

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours after a single dose administration.

  6. Objective response rate (ORR)

    ORR is defined as confirmed complete response (CR) or partial response (PR) based on RECIST (version 1.1) .

    Time frame: Baseline through up to 6 cycles or until disease progression (each cycle is 28 days)

  7. Progression-free survival (PFS)

    PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.

    Time frame: Baseline through up to 6 cycles or until disease progression (each cycle is 28 days)

  8. Overall survival (OS)

    Overall survival is defined as the time from randomization until death from any cause and is measured in the intent-to-treat population.

    Time frame: Baseline through up to 6 cycles or until disease progression (each cycle is 28 days)

07

Study locations

21 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Jun 2028, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Dec 13, 2023
StartActual
Feb 4, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06169579
Lead sponsor
Shenzhen NewDEL Biotech, Co., Ltd
Collaborators
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd., Sun Yat-Sen University Cancer Center
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Feb 4, 2024
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 21, 2026

Study contacts

Li Zhang, PhD
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRK/RET Inhibitor ND-003

Start the discussion